Innovation Activities and Developments

Learn more about the discoveries and innovations that take place at MSK every day. 

15 News Items found
MSK Named to Best Workplaces for Innovators 2025 List
MSK Named to Fast Company’s Best Workplaces for Innovators List

For the first time, MSK has been named one of Fast Company’s Best Workplaces for Innovators, ranking No. 9 out of 100 on its 2025 list of awardees.
MSK EBP Consulting Collaborates with HealthLinx to Bring Evidence-Based Practice to More Hospitals Across the U.S. Add to Default shortcuts Primary tabs Edit
MSK EBP Consulting Collaborates with HealthLinx to Bring Evidence-Based Practice to More Hospitals Across the U.S.

Memorial Sloan Kettering Cancer Center (MSK) recently executed a contract with HealthLinx, a consulting firm that helps hundreds of hospitals achieve Magnet® and Pathway to Excellence ® designation. Under the agreement, MSK’s EBP Consulting Service will provide training in MSK’s proprietary evidence-based practice (EBP) methodology directly to select HealthLinx clients who are looking to improve or enculturate EBP.
Nai-Kong Cheung
Dr. Nai-Kong Cheung honored with 2025 Lifetime Achievement Award from the Advances in Neuroblastoma Research Association

Dr. Nai-Kong V. Cheung, MD, PhD, the Enid A. Haupt Chair in Pediatric Oncology at MSK, was honored by the Advances in Neuroblastoma Research Association (ANRA) with its 2025 lifetime achievement award. An esteemed physician-scientist, Dr. Cheung leads a laboratory in Memorial Hospital Research Laboratories at MSK, which is focused on engineering antibodies and immune cells to treat both solid tumors and liquid tumors in children.
Danny Khalil, MD,PhD
Dr. Danny Khalil wins Harrington Discovery Institute 2025 Scholar-Innovator Award

Danny Khalil, MD, PhD, medical oncologist and immunotherapy specialist at Memorial Sloan Kettering Cancer Center (MSK), has won a 2025 Scholar-Innovator Award from the Harrington Discovery Institute.
William Tap
MSK Expands Collaboration with Curadev Through MSK Therapeutics Accelerator Program

Memorial Sloan Kettering Cancer Center (MSK) and Curadev Pharma, Inc., a biotechnology company developing novel immuno-oncology therapeutics, are expanding their collaboration through the MSK Therapeutics Accelerator program to advance the development of CRD3874-SI, Curadev’s first-in-class allosteric stimulator of interferon genes (STING) agonist for solid tumors.
Rick Peng announcing launch of 2025 iHub Challenge Cohort
MSK iHub Challenge 2025 Cohort Now Open for Applications

Memorial Sloan Kettering Cancer Center (MSK) is accepting applications for the 2025 Cohort of the MSK Innovation Hub (iHub) Challenge program. Digital health companies with innovations leveraging AI to address critical issues in the drug discovery process are encouraged to apply.
Eileen Flowers, PhD
MSK Therapeutics Accelerator Launches New Cohort Program

Scheduled to start in Summer 2025, this cohort program will facilitate tailored mentorship with MSK faculty, while providing insight into MSK's drug development resources and a pathway for future collaboration via the Accelerator.
Saad Nadeem, PhD, Assistant Attending Computer Scientist
MSK Partners with PathPresenter to Integrate New AI Module for Oncology Research

Memorial Sloan Kettering Cancer Center (MSK) is partnering with PathPresenter, a leader in digital pathology workflow software, to integrate DeepLIIF, MSK’s new artificial intelligence (AI) algorithm, into PathPresenter’s image management platform for oncology research.
Memorial Sloan Kettering Cancer Center and AWS to Accelerate AI-Driven Cancer Innovation
Memorial Sloan Kettering Cancer Center and AWS to Accelerate AI-Driven Cancer Innovation

Uniting MSK’s research and clinical expertise with AWS’s advanced cloud technologies is a bold step towards addressing one of the world’s most pressing health challenges.
MSK’s WOUND-Q™ Questionnaire is FDA-Qualified as a Medical Device Development Tool
MSK’s WOUND-Q™ Questionnaire is FDA-Qualified as a Medical Device Development Tool

The U.S. Food and Drug Administration (FDA) qualified MSK’s WOUND-Q™ questionnaire as a Medical Device Development Tool (MDDT) in November 2024.